Login to Your Account

Eleison Seeks Phase III Success with Glufosfamide

By Marie Powers
Staff Writer

Tuesday, October 8, 2013
Eleison Pharmaceuticals LLC moved lead compound glufosfamide into a Phase III study in second-line pancreatic cancer, seeking to achieve success in a drug that was a near-miss in previous hands.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription